O

Omeros Corp

D
OMER
USD
-0.095
(-2.1088%)
Market Closed
4,353.00
حجم التداول
-1.76
الربح لكل سهم
-
العائد الربحي
-1.328313
P/E
255,545,648.19
حجم السوق
اليوم
-2.1088%
1 اسبوع
8.088%
1 شهر
13.368%
6 اشهر
24.752%
12 اشهر
241.860%
بداية السنة
35.069%
كل الوقت
0%

Title:
Omeros Corp

Sector:
Healthcare
Industry:
Biotechnology
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
هل تحتاج مساعدة او لديك استفسار؟